Skip Soft Definitions and Focus on Hard Endpoints

Anthracycline cardiotoxicity (AC) is one of the most concerning cancer therapeutic adverse events and can be a limiting factor in treating hematological malignancies, breast cancers, and other solid tumors ([1–3][1]). One of the “holy grails” of cardio-oncology is to be able to predict which

Read the full article here

Related Articles